Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The 5-year programme award will support research on the DNA repair mechanisms that protect cancer cells from therapy, informing the development of future treatments.

Assoc Prof Peter McHugh (right) with Prof Chris Schofield (Department of Chemistry) and Prof Opher Gileadi (Nuffield Department of Medicine)

Cancer therapies such as chemotherapy and radiotherapy aim to kill cancer cells by causing damage to their DNA. However, cancer cells often resist treatment because they have mechanisms in place that allow them to repair their DNA. Understanding how this DNA repair takes place is essential to develop more effective cancer treatments.

Associate Professor Peter McHugh, a group leader at the MRC WIMM and the Department of Oncology, has been awarded a collaborative award by Cancer Research UK to investigate this problem. The project, to be developed in collaboration with Prof Chris Schofield (Department of Chemistry) and Prof Opher Gileadi (Nuffield Department of Medicine) will focus on human metallo-β-lactamase (MBL)-fold nucleases, important players in a cell’s DNA repair machinery. Using a combination of cell biology, genetics, structural biology and chemical biology, they hope to understand in detail how this machinery repairs DNA in a healthy context, and how it is exploited by cancer cells. These results will be used to develop a screen for potential drugs that can inhibit the activity of MBL-fold nucleases. These inhibitors could have antitumour properties or help make existing cancer therapies more efficient, as cancer cells would no longer be able to repair their DNA.

“By defining the mechanism of action of MBL-fold nucleases and identifying strategies for their inhibition, we will enable efforts to exploit this druggable target” said Assoc Prof McHugh. New drugs targeting MBL-fold nucleases could, in the future, be combined with existing therapies to increase their efficiency and reduce side-effects.

Similar stories

New Fellowship of the Association of Cancer Physicians

Many congratulations to Prof Adrian Harris (Department of Oncology), who has become a Fellow of the Association of Cancer Physicians.

New “molecular fibres” may help cells repair DNA

Research by the Blackford group has for the first time observed molecular fibres that may hold together sections of broken DNA in mitosis.

MRC WIMM researchers talk about their research on rare diseases

To mark rare disease day we asked our researchers to tell us more about the rare conditions that they study, and why their research is important.

MRC HIU Group Leader in team shortlisted for £20m CRUK Grand Challenge Award

An international team of scientists has been shortlisted out of 134 applications spanning 41 countries.

Successful CRUK Research Bursary for MRC WIMM Clinical Fellow

Many congratulations to Robert Watson, a NIHR Academic Clinical Fellow in the laboratory of Benjamin Fairfax. Robert was successful in his application for a CRUK pre-doctoral research bursary.

Regional Breast Cancer Academic Day marks NHS retirement for Prof Adrian Harris

This month the MRC WIMM hosted the annual Regional Breast Cancer Academic Day, an event that brings together breast cancer teams from across the Thames Valley region. This year’s symposium involved the participation of over 70 attendees, including nurses, clinical trial managers, researchers and doctors.